Stockwatch: Is the HCV party over?
This article was originally published in Scrip
Executive Summary
On the cusp of the full-year 2011 earnings season, investors still have an eye on a less tangible number. How many more acquisitions will there be of companies developing hepatitis C virus (HCV) anti-virals?